2025
Collaborating Across the Globe: The Yale-University of Jordan International Interprofessional Addiction Education Program
Muvvala S, Minahan-Rowley R, Al-Khateeb Y, Abu-Dahab R, Khoshnood K, Wazaify M, Tetrault J. Collaborating Across the Globe: The Yale-University of Jordan International Interprofessional Addiction Education Program. Substance Abuse 2025, 46: 1013-1018. PMID: 40913374, DOI: 10.1177/29767342251331389.Peer-Reviewed Original ResearchYale School of MedicineSubstance use disordersTraining programJoint training programsHealth care workforceAddiction medicineInternational conference presentationsGlobal public health challengePublic health challengePeer-reviewed articlesCare workforcePublished peer-reviewed articlesInterprofessional educationTreatment gapTreating substance use disordersKern modelSchool of MedicineHealth challengesConference presentationsTraining workshopsTraining opportunitiesEducation programsPublic healthSubstance useTwo-year programEmerging Therapeutics in the Treatment of Substance Use Disorders: A Focus on GLP-1 Receptor Agonists, D3R Antagonists, and CRF Antagonists
Draghmeh K, Fuehrlein B. Emerging Therapeutics in the Treatment of Substance Use Disorders: A Focus on GLP-1 Receptor Agonists, D3R Antagonists, and CRF Antagonists. Journal Of Integrative Neuroscience 2025, 24: 26361. PMID: 40302255, DOI: 10.31083/jin26361.Peer-Reviewed Original ResearchConceptsSubstance use disordersCorticotropin-releasing factorTreatment of substance use disordersCorticotropin-releasing factor antagonistTreating substance use disordersDrug-seeking behaviorDopamine D3 receptorGlucagon-like peptide-1Reduce substance useUse of alcoholAddiction processD3R antagonistsReward modulationRelapse preventionD3 receptorsUse disorderStimulant useSubstance useGlucagon-like peptide-1 receptor agonistsPrevent relapseReceptor agonistsTarget different aspectsSignificant public health challengeAntagonistDisordersAntiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel
Gandhi R, Landovitz R, Sax P, Smith D, Springer S, Günthard H, Thompson M, Bedimo R, Benson C, Buchbinder S, Crabtree-Ramirez B, del Rio C, Eaton E, Eron J, Hoy J, Lehmann C, Molina J, Jacobsen D, Saag M. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel. JAMA 2025, 333: 609-628. PMID: 39616604, DOI: 10.1001/jama.2024.24543.Peer-Reviewed Original ResearchAntiretroviral drugsHIV preventionSubstance use disordersLong-acting injectable therapyManagement of HIV infectionIntegrase strand transfer inhibitorsNucleotide reverse transcriptase inhibitorsStrand transfer inhibitorsSexually transmitted infectionsPeer-reviewed scientific conferencesDaily oral medicationReverse transcriptase inhibitorsLong-acting medicationsManagement of substance use disordersPrevention of HIVCardiovascular disease preventionTreating substance use disordersVirological failureAntiretroviral therapyHIV acquisitionHIV infectionHIV exposureInjection therapyDaily therapyLaboratory monitoring
2024
The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature
Pulido-Saavedra A, Borelli A, Kitaneh R, Alrafayia M, Jalilian-Khave L, Funaro M, Potenza M, Angarita G. The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature. Expert Opinion On Pharmacotherapy 2024, 26: 133-146. PMID: 39708346, PMCID: PMC11786980, DOI: 10.1080/14656566.2024.2446623.Peer-Reviewed Original ResearchConceptsTreatment of substance use disordersSubstance use disordersTreating substance use disordersPsychedelic agentsNarrative reviewReceptor agonistsClinical literatureReceptor antagonistNovel interventionsClinical evidenceFDA approvalPublic health issueDisordersReceptorsAgonistsTreatmentCravingPositive resultsPsychedelicsAbstinenceReviewed literatureAgentsHealth issuesAntagonistPrimary affinityOpioid and Substance Use Disorders
Gonzalez-Fiol A, Fardelmann K. Opioid and Substance Use Disorders. 2024, 323-333. DOI: 10.1007/978-3-031-62756-9_40.Peer-Reviewed Original ResearchSubstance use disordersUse disorderDSM-5 diagnostic criteriaTreating substance use disordersPregnant patientsDSM-5National Survey on Drug Use and HealthDrug Use and HealthPatterns of behaviorImpaired controlReferral to treatmentSedative hypnoticsBrief interventionDisordersFetal outcomesFetal morbidityDiagnostic criteriaIllicit drugsPregnant womenEvidence-based approachHealthcare providersPathological patternsTobacco productsSocial stigmaSocioeconomic demographicsPreparing Physicians to Treat Addiction: Inclusion of Dedicated Addiction Training During Internal Medicine Residency
Canver B, Liptak A, Clark K, Tetrault J, Holt S. Preparing Physicians to Treat Addiction: Inclusion of Dedicated Addiction Training During Internal Medicine Residency. Substance Abuse 2024, 45: 408-414. PMID: 38254274, DOI: 10.1177/29767342231224978.Peer-Reviewed Original ResearchSubstance use disordersAddiction medicine curriculaTreating substance use disordersMedicine residentsMedicine curriculumPrimary care residency programsStigmatizing languageResident primary care clinicResidency programsPrimary care trainingPrimary care clinicsManagement of substance use disordersInternal medicine residentsAddiction medicine trainingMedicine residency programsCare of patientsCare trainingSubstance use disorder pharmacotherapiesCare clinicsSubstance use treatmentMedicine trainingOutpatient addiction clinicAddiction curriculumQualitative interviewsFormal training
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply